Lexeo Therapeutics (LXEO) EBIAT (2022 - 2023)
Historic EBIAT for Lexeo Therapeutics (LXEO) over the last 2 years, with Q4 2023 value amounting to -$14.2 million.
- Lexeo Therapeutics' EBIAT rose 278.77% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 4809.19% down from last year.
- Latest data reveals that Lexeo Therapeutics reported EBIAT of -$14.2 million as of Q4 2023, which was up 278.77% from -$20.1 million recorded in Q3 2023.
- In the past 5 years, Lexeo Therapeutics' EBIAT registered a high of -$13.4 million during Q2 2023, and its lowest value of -$20.1 million during Q3 2023.